ASAM submitted a comment letter to the Department of Health and Human Services’ Assistant Secretary for Planning and Evaluation (ASPE) in response to an RFI required by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

ASAM joined the Partnership to Amend 42 CFR Part 2 in expressing appreciation for SAMHSA's issuance of a notice of proposed rulemaking to modify 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records.

Dr. Margaret Jarvis, Board Member of ASAM, participated in a congressional roundtable sponsored by the House Bipartisan Heroin and Opioid Task Force. At the event, Dr. Jarvis discussed the need for greater financial investment in demand-reduction interventions and emphasized the need for bold policy solutions to meet the scale of the opioid crisis.

ASAM supports the introduction of the Medical Marijuana Research Act, which would enable researchers to better study cannabis.

ASAM, working with the Partnership to Amend 42 CFR PArt 2, sent a letter urging lawmakers to align 42 CFR Part 2 with the Health Insurance Portability and Accountability Act (HIPAA)

ASAM applauds the introduction of the Cannabidiol and Marijuana Research Expansion Act, which would enable researchers to better study cannabis.

The Opioid Workforce Act of 2019 (H.R. 3414), introduced by Representatives Brad Schneider (D-IL), Susan Brooks (R-IN), Ann Kuster (D-NH), and Elise Stefanik (R-NY), would help address the national shortage of addiction physician specialists by increasing the number of resident physician positions available in hospitals that either have or are developing residency programs in addiction psychiatry or addiction medicine (or pain medicine).

Yngvild Olsen, MD, MPH urged lawmakers to expand access to evidence-based addiction treatment and invest more resources to address the addiction and overdose crisis during today’s House Committee on Oversight and Reform Hearing .